ALLMedicine™ Portal Hypertension Center

Dec 2nd, 2021 - Hepatic venous pressure gradient (HVPG) is considered the standard in quantifying portal hypertension, but can be unreliable in dialysis patients. A noninvasive ultrasound technique, subharmonic-aided pressure estimation (SHAPE), may be a valuable...

Nov 29th, 2021 - Portal hypertension due to cirrhosis is common among patients with hepatocellular carcinoma (HCC). This study aimed to compare the outcomes of partial hepatectomy in patients with HCC and clinically significant portal hypertension (CSPH) with or w...

Nov 23rd, 2021 - Gaucher disease (GD) is a rare autosomal recessive inherited disease caused by the deficiency of glucocerebrosidase and characterized by a broad spectrum of clinical manifestations, including hepatosplenomegaly, bone infiltration, and cytopenia. M...

Nov 23rd, 2021 - Acute variceal bleeding is a complication of portal hypertension, usually due to cirrhosis, with high morbidity and mortality. There are 3 scenarios for endoscopic treatment of esophageal varices: prevention of first variceal bleed, treatment of a...

Nov 23rd, 2021 - Portal hypertension is a complex syndrome with multiple clinical manifestations that develop in a variety of conditions and diseases. The spectrum of portal hypertension manifestations is wide and dependent on the physiologic site of increased por...

Aug 1st, 2021 - Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis/cirrhosis in asymptomatic patients at risk of developing clinically significant portal hypertension (CSPH, defined by a hepatic venous pressure gradient...

Aug 1st, 2021 - Primary biliary cholangitis (PBC) is a chronic inflammatory disease of the intra-hepatic bile ducts [1]. It is characterised biologically by chronic cholestasis associated with the presence of specific autoantibodies, and histologically by lesions...

May 8th, 2021 - Cirrhosis is a heterogeneous disease that cannot be studied as a single entity and is classified in two main prognostic stages: compensated and decompensated cirrhosis. Portal hypertension, characterized by a pathological increase of the portal pr...

Jan 26th, 2021 - Management of bleeding gastric varices (GV) presents a unique challenge for patients with portal hypertension. Despite over thirty years of diagnostic and treatment advances standardized practices for bleeding GV are lacking and unsupported by ade...

Mar 3rd, 2020 - These guidelines on transjugular intrahepatic portosystemic stent-shunt (TIPSS) in the management of portal hypertension have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG...

Nov 18th, 2021 - Liver cancer is the sixth most common cancer and the third leading cause of death from cancer worldwide (source: Globocan 2018). Hepatocellular carcinoma (HCC) represents 80-90% of liver cancers. Percutaneous thermal ablation (PTA) is a validated ...

Nov 18th, 2021 - This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various l...

Nov 11th, 2021 - Liver disease is one of the main causes of hospital admissions worldwide and the 12th leading cause of mortality in many countries. Among all etiologies (toxic-metabolites, viral, autoimmune, and genetic disorders), nonalcoholic fatty liver diseas...

Oct 29th, 2021 - Compensated advanced chronic liver disease (cACLD) commonly indicates severe fibrosis and compensated cirrhosis at risk of developing clinically significant portal hypertension (CSPH) and hepatic decompensation.The presence of CSPH (defined as hep...

Oct 26th, 2021 - Early diagnosis of portal hypertension is difficult as symptoms rarely manifest until the later stages of liver disease. Both cirrhotic and non-cirrhotic portal hypertension can result in life-threatening complications, the most frequent of which ...

Nov 3rd, 2021 - Takeaway The incidence of splanchnic vein thrombosis (SVT) remains significant in patients with acute pancreatitis. Treatment with anticoagulants improved the rate of recanalisation but increased the risk of haemorrhagic complications, without inc...

Oct 6th, 2021 - HEPZATO KIT (HEPZATO; melphalan hydrochloride for injection/hepatic delivery system) has demonstrated statistically significant benefit compared to best alternative care (BAC) in patients with liver-dominant metastatic ocular melanoma, according t...

Oct 6th, 2021 - Amit G. Singal, MD The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for patients with hepatocellular carcinoma (HCC) highlights the need for multidisciplinary care because of the increased risk of gastrointestinal (GI) bleedi...

Oct 6th, 2021 - Differences in germline and somatic BRCA mutations in pancreatic cancer, the role of molecular testing in hepatocellular carcinoma (HCC), and treatment options for patients with BRAF-mutant, microsatellite instability–high (MSI-H) colorectal cance...

May 27th, 2021 - FDA on Wednesday restricted the use of obeticholic acid (Ocaliva) in primary biliary cholangitis (PBC) due to the risk of serious liver injury in patients with advanced cirrhosis. Serious side effects, such as liver failure or the urgent need for ...